⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ERNA News
Ernexa Therapeutics Inc. Common Stock
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
globenewswire.com
ERNA
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
globenewswire.com
ERNA
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
globenewswire.com
ERNA
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
globenewswire.com
ERNA
Form 8-K
sec.gov
ERNA
ERNAW
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
globenewswire.com
ERNA
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
globenewswire.com
ERNA
Form 8-K
sec.gov
ERNAW
ERNA
Form 8-K
sec.gov
ERNA
ERNAW
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
globenewswire.com
ERNA